ArticleOncotarget2016
Concerted action of IFN-α and IFN-λ induces local NK cell immunity and halts cancer growth.
Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 38 citations in OpenAlex.
- Experimental models in immuno-oncology and their translational impact.Discover oncology · 2026Review
- Interferon lambda in anti-viral defense and cancer: dual roles, mechanism and therapeutic potential.Journal of translational medicine · 2026Review
- Modulation of gut microbiota and its metabolite Equol by Huaier granule suppresses hepatocellular carcinoma via the gut-liver axis.NPJ biofilms and microbiomes · 2026Article
- Interferon Lambda: The Next Frontier in Antiviral Therapy?Pharmaceuticals (Basel, Switzerland) · 2025Review
- Dys-regulated phosphatidylserine externalization as a cell intrinsic immune escape mechanism in cancer.Cell communication and signaling : CCS · 2025Review
- Phosphatidylserine (PS)-targeting chimeric Interferon (IFN) fusion proteins for anti-tumor applications.bioRxiv : the preprint server for biology · 2025Article
- Type III interferon exerts thymic stromal lymphopoietin in mediating adaptive antiviral immune response.Frontiers in immunology · 2023Review
- Natural Killer-Dendritic Cell Interactions in Liver Cancer: Implications for Immunotherapy.Cancers · 2021Review
- Tumor cell intrinsic RON signaling suppresses innate immune responses in breast cancer through inhibition of IRAK4 signaling.Cancer letters · 2021Article
- Double-edged effects of interferons on the regulation of cancer-immunity cycle.Oncoimmunology · 2021Review
- A role for the immune system in advanced laryngeal cancer.Scientific reports · 2020Article
- Recent Advances in Molecular Mechanisms of the NKG2D Pathway in Hepatocellular Carcinoma.Biomolecules · 2020Review
- Genomic variability of within-host hepatitis C variants in acute infection.Journal of viral hepatitis · 2019Article
- Targeting IL-10 Family Cytokines for the Treatment of Human Diseases.Cold Spring Harbor perspectives in biology · 2019Review
- Hepatic Natural Killer Cells: Organ-Specific Sentinels of Liver Immune Homeostasis and Physiopathology.Frontiers in immunology · 2019Review
- Natural killer cells in liver diseases.Frontiers of medicine · 2018Review
- In vitro differentiated plasmacytoid dendritic cells as a tool to induce anti-leukemia activity of natural killer cells.Cancer immunology, immunotherapy : CII · 2017Article
- Natural killer cell activity for IFN-gamma production as a supportive diagnostic marker for gastric cancer.Oncotarget · 2017Article
- Contribution of type III interferons to antiviral immunity: location, location, location.The Journal of biological chemistry · 2017Review
- Interferon (IFN)-λ Takes the Helm: Immunomodulatory Roles of Type III IFNs.Frontiers in immunology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
Abstract
Hepatocellular carcinoma (HCC) is the most prevalent type of liver cancer. No significant improvement has been reported with currently available systemic therapies. IFN-α has been tested in both clinic and animal models and only moderate benefits have been observed. In animal models, similar modest antitumor efficacy has also been reported for IFN-λ, a new type of IFN that acts through its own receptor complex. In the present study, the antitumor efficacy of the combination of IFN-α and IFN-λ was tested in the BNL mouse hepatoma model. This study was accomplished by using either engineered tumor cells (IFN-α/IFN-λ gene therapy) or by directly injecting tumor-bearing mice with IFN-α/IFN-λ. Both approaches demonstrated that IFN-α/IFN-λ combination therapy was more efficacious than IFN monotherapy based on either IFN-α or IFN-λ. In complement to tumor surgery, IFN-α/IFN-λ combination induced complete tumor remission. Highest antitumor efficacy has been obtained following local administration of IFN-α/IFN-λ combination at the tumor site that was associated with strong NK cells tumor infiltration. This supports the use of IFN-α/IFN-λ combination as a new cancer immunotherapy for stimulating antitumor response after cancer surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.